{"entity":{"id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","aka":[],"tldr":"A phase 2 trial of Zanubrutinib in chronic lymphocytic leukaemia, run by Curis, Inc., now recruiting.","summary":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies is a phase 2 interventional study registered as NCT07271667 by Curis, Inc., with 108 participants planned, started 2026-04-23 and due to reach its primary completion in 2027-11. Interventions recorded: Emavusertib and Zanubrutinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07271667","url":"https://clinicaltrials.gov/study/NCT07271667"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["zanubrutinib"],"companies":["curis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07271667","phase":"2","setting":"A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies","sponsor":"Curis, Inc.","enrolled":108,"outcomes":[]},"route":"/trials/nct07271667/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"emavusertib","kind":"drug","name":"Emavusertib","route":"/drugs/emavusertib/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"company":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/"}]}}